Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Prostate Cancer Resource Center

News
Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer
02/23/2024

Allison Casey 

Allison Casey 
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results...
02/23/2024
Oncology
From Oncology
Alexandra Sokolova video thumbnail.
Videos
Highlights and Key Takeaways in Prostate Cancer From ASCO GU 2024
02/15/2024

Featuring Alexandra Sokolova, MD

Featuring Alexandra Sokolova, MD ...
Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.
Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.
Alexandra Sokolova, MD, shares...
02/15/2024
Journal of Clinical Pathways
News
A Look at the Updates in the NCCN Clinical Practice Guidelines For Prostate Cancer
02/09/2024

By Emry Lloyd

By Emry Lloyd
Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.
Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.
Get a summary of the changes in...
02/09/2024
Journal of Clinical Pathways
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024

Stephanie Holland 

Stephanie Holland 
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology
From Oncology
Neal Shore, MD, FACS.
Videos
Outcomes of Men With High-Risk, Biochemically Recurrent Prostate Cancer Who Discontinued Enzalutamide Monotherapy in the EMBARK Study
01/18/2024

Featuring Neal Shore, MD, FACS

Featuring Neal Shore, MD, FACS ...
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses...
01/18/2024
Journal of Clinical Pathways
News
Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer
01/05/2024
Allison Casey
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet...
01/05/2024
Oncology
From Oncology
Research Reports
The Impact of Social Determinants of Health Beyond Race on Survival in Metastatic Prostate Cancer: A Systematic Literature Review
12/14/2023
Stephen J. Freedland, MD
Imtiaz A. Samjoo, MSc, PhD
Emily Rosta, MSc
Austin Lansing, MSc
Alexandra Hall, MPH
Manvir Rai, BSc
Alexander Niyazov, PharmD, MPH
Jonathan L. Nazari, PharmD
Bhakti Arondekar, PhD, MBA
A systematic literature review by Stephen J. Freedland, MD, and colleagues summarizes the current evidence relating to social determinants of health beyond race and survival in patients with metastatic prostate cancer.
A systematic literature review by Stephen J. Freedland, MD, and colleagues summarizes the current evidence relating to social determinants of health beyond race and survival in patients with metastatic prostate cancer.
A systematic literature review...
12/14/2023
Journal of Clinical Pathways
Manish Kohli
Videos
Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
News
Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer
03/03/2023

Grace Taylor

Grace Taylor
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers...
03/03/2023
Journal of Clinical Pathways
News
Health Care Resource Utilization and Costs Associated With Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer
06/09/2022

Ellen Kurek

Ellen Kurek
Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.
Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.
Study results show direct...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Real-world Treatment Patterns for Patients With Metastatic Castration-Resistant Prostate Cancer
06/06/2022

Robert Fee

Robert Fee
Although numerous treatments with different mechanisms of action are approved for metastatic castration-resistant prostate cancer (mCRPC), the sequencing for management of these patients has been evolving post availability of trials.
Although numerous treatments with different mechanisms of action are approved for metastatic castration-resistant prostate cancer (mCRPC), the sequencing for management of these patients has been evolving post availability of trials.
Although numerous treatments...
06/06/2022
Journal of Clinical Pathways

Expert Insights

Alexandra Sokolova video thumbnail.
Videos
Highlights and Key Takeaways in Prostate Cancer From ASCO GU 2024
02/15/2024

Featuring Alexandra Sokolova, MD

Featuring Alexandra Sokolova, MD ...
Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.
Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.
Alexandra Sokolova, MD, shares...
02/15/2024
Journal of Clinical Pathways
Neal Shore, MD, FACS.
Videos
Outcomes of Men With High-Risk, Biochemically Recurrent Prostate Cancer Who Discontinued Enzalutamide Monotherapy in the EMBARK Study
01/18/2024

Featuring Neal Shore, MD, FACS

Featuring Neal Shore, MD, FACS ...
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
Neal Shore, MD, FACS, discusses...
01/18/2024
Journal of Clinical Pathways
Manish Kohli
Videos
Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
Alicia Morgans, MD, MPH, Dana-Farber Cancer Institute
Videos
NCCN Guidelines for Treating Metastatic Castration-Resistant Prostate Cancer: Biomarker-Selected Patients
01/12/2022
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and...
01/12/2022
Journal of Clinical Pathways
Daniel George, MD
Videos
Real-World Utilization of Advanced Therapies Among Patients With Metastatic CSPC
10/07/2021
Daniel George, MD, discusses results from a study analyzing real-world utilization of advanced therapies for patients with metastatic CSPC over time by metastatic site and age.
Daniel George, MD, discusses results from a study analyzing real-world utilization of advanced therapies for patients with metastatic CSPC over time by metastatic site and age.
Daniel George, MD, discusses...
10/07/2021
Journal of Clinical Pathways
Real-World Impact of Leuprolide Acetate Late Dosing on Testosterone Suppression for Prostate Cancer
Videos
Real-World Impact of Leuprolide Acetate Late Dosing on Testosterone Suppression for Prostate Cancer
05/04/2021
Lucio Gordan, MD, discusses results from a study analyzing the impact of late dosing of two leuprolide acetate formulations on testosterone suppression for patients with prostate cancer.
Lucio Gordan, MD, discusses results from a study analyzing the impact of late dosing of two leuprolide acetate formulations on testosterone suppression for patients with prostate cancer.
Lucio Gordan, MD, discusses...
05/04/2021
Journal of Clinical Pathways
Clinical Outcomes With Early vs Late Ra-223 for Patients With Metastatic CRPC
Videos
Clinical Outcomes With Early vs Late Ra-223 for Patients With Metastatic CRPC
04/23/2021
Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Richard Lee-Ying, MD, discusses...
04/23/2021
Journal of Clinical Pathways
Prostate Genetic Testing Station Increases Patient Access to Genetic Testing and Counseling
Videos
Prostate Genetic Testing Station Increases Patient Access to Genetic Testing and Counseling
04/21/2021
Barry Tong, CGC, MS, MPH, discusses a study evaluating the effectiveness of a prostate Genetic Testing Station at UCSF and compared these outcomes to those of a previously implemented take-home method.
Barry Tong, CGC, MS, MPH, discusses a study evaluating the effectiveness of a prostate Genetic Testing Station at UCSF and compared these outcomes to those of a previously implemented take-home method.
Barry Tong, CGC, MS, MPH,...
04/21/2021
Journal of Clinical Pathways
Medicare Reimbursement Trends for Gynecologic and Urologic Procedures
Videos
Medicare Reimbursement Trends for Gynecologic and Urologic Procedures
03/30/2021
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and prostatectomy procedures between 2010 and 2019 and comparing these to minimally invasive approaches.
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and prostatectomy procedures between 2010 and 2019 and comparing these to minimally invasive approaches.
Sandeep Voleti, BS, discusses a...
03/30/2021
Journal of Clinical Pathways
Prescribing Patterns in Metastatic Castrate-Sensitive Prostate Cancer
Insights From ASCO 2021
Prescribing Patterns in Metastatic Castrate-Sensitive Prostate Cancer
03/23/2021
Nataliya Mar, MD, UC Irvine Medical Center, Orange, CA, discusses results from a study exploring prescribing among patients with metastatic castrate-sensitive prostate cancer (CSPC). These results were presented at the virtual 2021 ASCO...
Nataliya Mar, MD, UC Irvine Medical Center, Orange, CA, discusses results from a study exploring prescribing among patients with metastatic castrate-sensitive prostate cancer (CSPC). These results were presented at the virtual 2021 ASCO...
Nataliya Mar, MD, UC Irvine...
03/23/2021
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 2)
05/20/2024
Michael Kolodziej, MD
John Hennessy, MBA
In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...
In part two of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into the other main stakeholders in health care costs: pharmaceutical manufacturers and providers. They discuss how these...
In part two of this two-part...
05/20/2024
Cancer Care Business Exchange
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways

Newsfeed

News
Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer
02/23/2024

Allison Casey 

Allison Casey 
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...
According to interim results...
02/23/2024
Oncology
News
A Look at the Updates in the NCCN Clinical Practice Guidelines For Prostate Cancer
02/09/2024

By Emry Lloyd

By Emry Lloyd
Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.
Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.
Get a summary of the changes in...
02/09/2024
Journal of Clinical Pathways
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024

Stephanie Holland 

Stephanie Holland 
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology
News
Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer
01/05/2024
Allison Casey
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.
A real world study found triplet...
01/05/2024
Oncology
News
Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer
03/03/2023

Grace Taylor

Grace Taylor
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers...
03/03/2023
Journal of Clinical Pathways
News
Health Care Resource Utilization and Costs Associated With Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer
06/09/2022

Ellen Kurek

Ellen Kurek
Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.
Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.
Study results show direct...
06/09/2022
Journal of Clinical Pathways
News
In Patients With Unfavorable Intermediate-Risk Prostate Cancer, Brachytherapy Improved Overall Survival Compared with External-Beam Radiotherapy
05/18/2022

Ellen Kurek

Ellen Kurek
Researchers reviewed the National Cancer Database records of nearly 32,000 men diagnosed with UIR prostate cancer to determine if men treated with brachytherapy had rates of survival comparable with those of men treated with EBRT.
Researchers reviewed the National Cancer Database records of nearly 32,000 men diagnosed with UIR prostate cancer to determine if men treated with brachytherapy had rates of survival comparable with those of men treated with EBRT.
Researchers reviewed the...
05/18/2022
Journal of Clinical Pathways
News
Comparing Costs and Health Care Resource Utilization Among Patients With Metastatic, Castration-Resistant vs Nonmetastatic Prostate Cancer
04/19/2022

Ellen Kurek

Ellen Kurek
Findings from a retrospective cohort study suggest that patients with metastatic, castration-resistant prostate cancer experience higher costs, and require more outpatient services, compared with those with nonmetastatic cancer.
Findings from a retrospective cohort study suggest that patients with metastatic, castration-resistant prostate cancer experience higher costs, and require more outpatient services, compared with those with nonmetastatic cancer.
Findings from a retrospective...
04/19/2022
Journal of Clinical Pathways
News
Health Care Costs and Utilization Associated With Open vs Robotic-Assisted Radical Prostatectomy
02/22/2022

Janelle Bradley

Janelle Bradley
Study findings suggest that lower postdischarge health care utilization after robotic-assisted prostatectomy may offset the higher costs during the index hospitalization.
Study findings suggest that lower postdischarge health care utilization after robotic-assisted prostatectomy may offset the higher costs during the index hospitalization.
Study findings suggest that...
02/22/2022
Journal of Clinical Pathways
News
Systematic Review Highlights Complexity of Cost-Effectiveness Models in Prostate Cancer
02/22/2022

Janelle Bradley

Janelle Bradley
This systematic review of cost-effectiveness literature for novel diagnostic methods in prostate cancer shows that most studies have found novel methods to be more cost-effective than standard of care.
This systematic review of cost-effectiveness literature for novel diagnostic methods in prostate cancer shows that most studies have found novel methods to be more cost-effective than standard of care.
This systematic review of...
02/22/2022
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
04/11/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
04/11/2024
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Grace Taylor, MS, MA
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology

Interactive Features

Quiz
Quiz: Costs and Health Care Resource Utilization in Patients With Metastatic, Castration-Resistant vs Nonmetastatic Prostate Cancer
05/02/2022
True or False: Compared with patients with nonmetastatic, hormone-sensitive prostate cancer (HSPC), overall annual out-of-pocket costs were higher for patients with metastatic, HSPC.
True or False: Compared with patients with nonmetastatic, hormone-sensitive prostate cancer (HSPC), overall annual out-of-pocket costs were higher for patients with metastatic, HSPC.
True or False: Compared with...
05/02/2022
Journal of Clinical Pathways
Quiz
Quiz: Overall Survival in Patients With Prostate Cancer Receiving Enzalutamide or Abiraterone
01/27/2022
True or False: Prostate-specific antigen progression at 4 weeks after enzalutamide or abiraterone is associated with shorter overall survival
True or False: Prostate-specific antigen progression at 4 weeks after enzalutamide or abiraterone is associated with shorter overall survival
True or False: Prostate-specific...
01/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Managing Localized, Intermediate-Risk Prostate Cancer
05/05/2021
05/05/2021
Journal of Clinical Pathways
Quiz
Quiz: Financial Burden of Contemporary Treatments for Prostate Cancer
02/08/2021
02/08/2021
Journal of Clinical Pathways
Quiz
Quiz: Costs of Darolutamide for Castration-Resistant Prostate Cancer
12/12/2020
12/12/2020
Journal of Clinical Pathways
Quiz
Quiz: Does Adjuvant Radiotherapy Improve EFS in Prostate Cancer?
11/25/2020
11/25/2020
Journal of Clinical Pathways
Quiz
Quiz: Does Cabazitaxel Reduce Quality of Life in Metastatic Prostate Cancer?
10/09/2020
10/09/2020
Journal of Clinical Pathways
Quiz
Quiz: Improving Event-Free Survival in Men With Prostate Cancer With Adjuvant Radiotherapy
10/02/2020
10/02/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement